SAN FRANCISCO, Jan. 3, 2024 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotechnology company committed to advancing oligonucleotide therapies, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB) infection, today announced that Dr.

旧金山，2024年1月3日/PRNewswire/--AusperBio Therapeutics，Inc.和Ausper Biopharma Co.，Ltd.（合称AusperBio），一家致力于推进寡核苷酸治疗的临床阶段生物技术公司，主要致力于实现慢性乙型肝炎（CHB）感染的功能性治愈，今天宣布。

Will Wei has joined the company as Head of CMC, SVP..

威尔·魏（Will Wei）已加入该公司，担任高级副总裁CMC负责人。。

'We are excited to welcome Dr. Wei to AusperBio's leadership team at this pivotal time for the company,' said Dr. Guofeng Cheng, chief executive officer. 'Will's depth and breadth of experience in end-to-end CMC operations, strategic insight will be instrumental in executing our plans, propelling our pipeline, and navigating the dynamic landscape of drug development.'.

首席执行官郭峰（音译）说，我们很高兴在这个公司的关键时刻欢迎魏博士加入AusperBio的领导团队威尔在端到端CMC运营方面的深度和广度经验，战略洞察力将有助于执行我们的计划，推动我们的管道，并驾驭药物开发的动态格局。”。

Bringing over two decades of outstanding leadership in the biotech and pharmaceutical industry, Dr. Wei has excelled across critical domains in drug development. Previously held key leadership roles at global pharmaceutical companies such as GSK as a Director of CMC, and Roche as a Senior Director of CMC, Dr.

Wei博士在生物技术和制药行业拥有20多年的杰出领导才能，在药物开发的关键领域表现出色。葛兰素史克（GSK）担任CMC董事，罗氏（Roche）担任CMC高级董事。

Wei spearheaded teams responsible for process development, clinical supply chain management, and successful regulatory submissions for both China and Global markets..

魏带领团队负责流程开发、临床供应链管理以及中国和全球市场的成功监管提交。。

'Joining AusperBio is both an honor and an exciting opportunity. I am inspired by AusperBio's mission, and extremely impressed by the clinical data and the forging-ahead development speed of AHB-137 program,' said Dr. Wei. 'I'm excited to lead and collaborate with the outstanding team, building upon the Company's robust scientific foundation, to advance HBV cure and beyond and make a meaningful impact on patient care.'.

“加入AusperBio既是一种荣誉，也是一个令人兴奋的机会。Wei博士说，我受到AusperBio使命的鼓舞，对AHB-137项目的临床数据和不断前进的发展速度印象深刻。我很高兴能够领导优秀团队并与之合作，以公司强大的科学基础为基础，推进HBV治愈和超越，并对患者护理产生有意义的影响。

Dr. Wei earned his Ph.D. in the Department of Organic Chemistry at the University of Lausanne in Switzerland and completed his postdoctoral training at The Scripps Research Institute.

魏博士在瑞士洛桑大学有机化学系获得博士学位，并在斯克里普斯研究所完成博士后培训。

About AusperBio.

关于奥地利。

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO platform with novel insights into ASO design and optimization to substantially enhance the current ASO therapeutics.

AusperBio是一家临床阶段的生物制药公司，在美国和中国均有业务，致力于推进用于转化疗法的寡核苷酸和靶向递送技术，最初专注于治疗慢性乙型肝炎。该公司开发了专有的Med Oligo™ASO平台具有对ASO设计和优化的新颖见解，可大大增强当前的ASO治疗方法。

Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligos™ Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases..

结合高效的靶向递送偶联技术，模块化Med寡核苷酸™该平台使ASO疗法能够治疗广泛的病毒感染，代谢状况，遗传疾病和免疫疾病。。

Media ContactEmail: [email protected]

媒体联系人电子邮件：[受电子邮件保护]

Investor ContactTel: 650-888-1756 (US)Email: [email protected]

投资者联系电话：650-888-1756（美国）电子邮件：[受电子邮件保护]

SOURCE AusperBio Therapeutics Inc.

Source Ausperbio Therapeutics公司。